Key clinical point: This meta-analysis suggests that the risk for cancer in patients with multiple sclerosis (MS) is less than the general population.
Major finding: The pooled relative risk (RR) of developing cancer was estimated as 0.83 ( P less than .001), which shows that risk for cancer was 17% less in patients with MS than the general population. The RR of developing cancer in MS individuals differed between studies ranging from 0.7 to 1.67.
Study details: A systematic review and meta-analysis of 5 studies.
Disclosures: The study received no funding. The authors declared no conflicts of interest.
Citation: Ghajarzadeh M et al. Autoimmun Rev. 2020 Aug 13. doi: 10.1016/j.autrev.2020.102650 .